Claudia Balducci

List of Publications by Year
in descending order

62	3,765	109321	128289
papers	citations	35 h-index	60 g-index

66	66	66	5507
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A critical appraisal of tauâ€targeting therapies for primary and secondary tauopathies. Alzheimer's and Dementia, 2022, 18, 1008-1037.	0.8	29
2	The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimerâ€™s disease. Molecular Therapy, 2022, 30, 2474-2490.	8.2	15
3	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimerâ€™s mice. Cell Death and Differentiation, 2021, 28, 203-218.	11.2	63
4	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. Progress in Molecular Biology and Translational Science, 2021, 177, 175-202.	1.7	21
5	Sleep inhibition induced by amyloidâ€Î²2 oligomers is mediated by the cellular prion protein. Journal of Sleep Research, 2021, 30, e13187.	3.2	5
6	Accelerating Alzheimerâ€™s disease drug discovery and development: whatâ€™s the way forward?. Expert Opinion on Drug Discovery, 2021, 16, 727-735.	5.0	9
7	Deletion of calcineurin from astrocytes reproduces proteome signature of Alzheimer's disease and epilepsy and predisposes to seizures. Cell Calcium, 2021, 100, 102480.	2.4	6
8	FlavonoidâEDerived Human Phenylâ€Î³â€Valerolactone Metabolites Selectively Detoxify Amyloidâ€Î²2 Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease. Molecular Nutrition and Food Research, 2020, 64, e1900890.	3.3	24
9	Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntingtonâ€™s Disease. Molecular Neurobiology, 2020, 57, 1889-1903.	4.0	38
10	Assessment of plaque morphology in Alzheimerâ€™s mouse cerebellum using three-dimensional X-ray phase-based virtual histology. Scientific Reports, 2020, 10, 11233.	3.3	19
11	X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases. Frontiers in Neuroscience, 2020, 14, 584161.	2.8	12
12	Doxycycline for Alzheimerâ€™s Disease: Fighting Î²-Amyloid Oligomers and Neuroinflammation. Frontiers in Pharmacology, 2019, 10, 738.	3.5	58
13	Biophysical and in Vivo Studies Identify a New Natural-Based Polyphenol, Counteracting Aβ2 Oligomerization in Vitro and Aβ2 Oligomer-Mediated Memory Impairment and Neuroinflammation in an Acute Mouse Model of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 4462-4475.	3.5	23
14	Neuroinflammation and the Gut Microbiota: Possible Alternative Therapeutic Targets to Counteract Alzheimerâ€™s Disease?. Frontiers in Aging Neuroscience, 2019, 11, 284.	3.4	95
15	Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. Brain, 2019, 142, 249-254.	7.6	38
16	Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 32-40.	2.5	46
17	Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. NeuroImage, 2019, 184, 490-495.	4.2	56
18	Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. Brain, Behavior, and Immunity, 2018, 69, 591-602.	4.1	55

#	Article	IF	Citations
19	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. ACS Chemical Neuroscience, 2018, 9, 1591-1606.	3.5	21
20	Novel targets in Alzheimerâ€™s disease: A special focus on microglia. Pharmacological Research, 2018, 130, 402-413.	7.1	46
21	Alzheimerâ€™s Disease, Oligomers, and Inflammation. Journal of Alzheimer's Disease, 2018, 62, 1261-1276.	2.6	141
22	Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 609-618.	3.3	109
23	Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. Neurobiology of Aging, 2018, 70, 128-139.	3.1	52
24	Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by Î²-amyloid oligomers in an acute mouse model of Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2017, 60, 188-197.	4.1	123
25	Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. Journal of Controlled Release, 2017, 258, 121-129.	9.9	40
26	Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's AÎ² peptide. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 723-732.	3.3	47
27	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-Î² Oligomers. Journal of Alzheimer's Disease, 2016, 53, 1485-1497.	2.6	12
28	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. Movement Disorders, 2016, 31, 771-781.	3.9	88
29	Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimerâ€™s disease murine model. Nano Research, 2016, 9, 2190-2201.	10.4	13
30	Internalization of nanopolymeric tracers does not alter characteristics of placental cells. Journal of Cellular and Molecular Medicine, 2016, 20, 1036-1048.	3.6	4
31	Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. Neurobiology of Aging, 2015, 36, 776-788.	3.1	25
32	Transgenic Fatal Familial Insomnia Mice Indicate Prion Infectivity-Independent Mechanisms of Pathogenesis and Phenotypic Expression of Disease. PLoS Pathogens, 2015, 11, e1004796.	4.7	61
33	The Continuing Failure of Bexarotene in Alzheimerâ€™s Disease Mice. Journal of Alzheimer's Disease, 2015, 46, 471-482.	2.6	28
34	Multifunctional Liposomes Reduce Brain Î²-Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models. Journal of Neuroscience, 2014, 34, 14022-14031.	3.6	141
35	In Vivo Application of beta Amyloid Oligomers: A Simple Tool to Evaluate Mechanisms of Action and New Therapeutic Approaches. Current Pharmaceutical Design, 2014, 20, 2491-2505.	1.9	53
36	The neurodegeneration in Alzheimer disease and the prion protein. Prion, 2013, 7, 60-65.	1.8	12

#	Article	IF	Citations
37	An N-terminal Fragment of the Prion Protein Binds to Amyloid-Î² Oligomers and Inhibits Their Neurotoxicity in Vivo. Journal of Biological Chemistry, 2013, 288, 7857-7866.	3.4	162
38	The Î³-Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 24, 799-816.	2.6	53
39	APP Transgenic Mice: Their Use and Limitations. NeuroMolecular Medicine, 2011, 13, 117-137.	3.4	69
40	c-Jun N-terminal Kinase Regulates Soluble AÎ² Oligomers and Cognitive Impairment in AD Mouse Model. Journal of Biological Chemistry, 2011, 286, 43871-43880.	3.4	74
41	Î²-amyloid oligomers and prion protein. Prion, 2011, 5, 10-15.	1.8	22
42	Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. Gene Therapy, 2010, 17, 643-652.	4.5	62
43	Cognitive Deficits Associated with Alteration of Synaptic Metaplasticity Precede Plaque Deposition in AÎ²PP23 Transgenic Mice. Journal of Alzheimer's Disease, 2010, 21, 1367-1381.	2.6	35
44	Synthetic amyloid-Î² oligomers impair long-term memory independently of cellular prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2295-2300.	7.1	435
45	Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimerâ€™s disease. Brain, 2010, 133, 3323-3335.	7.6	71
46	Neuropeptide Y Overexpression Using Recombinant Adenoassociated Viral Vectors. Neurotherapeutics, 2009, 6, 300-306.	4.4	32
47	NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. Hippocampus, 2008, 18, 564-574.	1.9	55
48	Mutant Prion Protein Expression Causes Motor and Memory Deficits and Abnormal Sleep Patterns in a Transgenic Mouse Model. Neuron, 2008, 60, 598-609.	8.1	97
49	Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain, 2008, 131, 1506-1515.	7.6	146
50	Dissociable Contribution of 5-HT1A and 5-HT2A Receptors in the Medial Prefrontal Cortex to Different Aspects of Executive Control such as Impulsivity and Compulsive Perseveration in Rats. Neuropsychopharmacology, 2006, 31, 757-767.	5.4	162
51	The Serotonin 5-HT2A Receptors Antagonist M100907 Prevents Impairment in Attentional Performance by NMDA Receptor Blockade in the Rat Prefrontal Cortex. Neuropsychopharmacology, 2004, 29, 1637-1647.	5.4	89
52	Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAYÂ100635. Psychopharmacology, 2003, 167, 28-36.	3.1	37
53	Reduced anxiety and improved stress coping ability in mice lacking NPYâ€Y2 receptors. European Journal of Neuroscience, 2003, 18, 143-148.	2.6	173
54	Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology, 2002, 160, 113-121.	3.1	75

#	Article	IF	Citations
55	Stimulation of 5-HT 1A receptors in the dorsal raphe ameliorates the impairment of spatial learning caused by intrahippocampal 7-chloro-kynurenic acid in naive and pretrained rats. Psychopharmacology, 2001, 158, 39-47.	3.1	26
56	Low doses of 8-OH-DPAT prevent the impairment of spatial learning caused by intrahippocampal scopolamine through 5-HT1A receptors in the dorsal raphe. British Journal of Pharmacology, 2000, 131, 375-381.	5.4	34
57	S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. British Journal of Pharmacology, 1999, 128, 1207-1214.	5.4	41
58	WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors. Neuropharmacology, 1999, 38, 1165-1173.	4.1	46
59	Gamma-Hydroxybutyric Acid Decreases Intravenous Cocaine Self-Administration in Rats. Pharmacology Biochemistry and Behavior, 1998, 59, 697-702.	2.9	12
60	Dextromethorphan reduces intravenous cocaine self-administration in the rat. European Journal of Pharmacology, 1997, 321, 279-283.	3.5	51
61	Dopamine partial receptor agonists reduce ethanol intake in the rat. European Journal of Pharmacology, 1996, 296, 233-238.	3.5	25
62	Inhibition of Nitric Oxide Synthesis Reduces Intravenous Cocaine Self-administration in the Rat. Neuropharmacology, 1996, 35, 1811-1814.	4.1	32